Bionano Genomics
9640 Towne Centre Drive, Ste. 100
San Diego
California
92121
United States
Tel: 858-888-7600
Fax: 858-888-7601
Website: http://www.bionanogenomics.com/
68 articles about Bionano Genomics
-
Bionano to Report First Quarter 2023 Financial Results and Host a Conference Call and Webcast on May 9, 2023
5/2/2023
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Tuesday, May 9, 2023, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2023 and to highlight recent corporate progress.
-
Clinical Catch-Up: January 10-14
1/17/2022
Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look. -
While the space is just beginning to emerge, therapies for long-haul COVID-19 patients are still very much an unmet need.
-
When Bionano Genomics acquired Lineagen, Inc. in August, the genomic analysis company gained the final piece it needed to provide comprehensive structural variation detection for researchers and drug developers and a reimbursement pathway for clinicians who want to use its technology to replace c...
-
BioSpace Movers & Shakers, Aug. 21
8/21/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 27, 2020.
-
This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 31, 2020.
-
Breakthrough Findings in Leukemias Presented at ASH 2019 Demonstrate Bionano Saphyr's Potential to Replace All Cytogenetic Methods and Show Additional Clinical Utility
12/5/2019
Bionano’s new DNA Isolation Kit for Bone Marrow Aspirates enables routine clinical analysis of Leukemia samples.
-
Takeaways from AMP 2019 in Baltimore: Users of Bionano's Saphyr System Presented Results from Multiple Studies Demonstrating the System's Utility for a Variety of Disease Indications
11/12/2019
Saphyr provides a platform that streamlines traditional workflows and provides a path to solving previously intractable scientific questions connected to the mechanisms of disease
-
Bionano Genomics Reports Third Quarter 2019 Financial Results and Provides Business Update
11/7/2019
Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today reported its financial results for the third quarter and nine months ended September 30, 2019 and provided a business update.
-
Novogene Adopts Bionano's Saphyr System Adding Saphyr's Ultra-Sensitive and Ultra-Specific Structural Variation Detection to their Repertoire of Services
11/6/2019
Novogene’s global customers will now have a high-throughput solution for long-read genome analysis enabling clinical-grade structural variation discovery and platinum genome assembly
-
Bionano Genomics to Report Third Quarter 2019 Financial Results and Host a Conference Call and Webcast on November 7
11/4/2019
Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today announced that it will host a conference call and live webcast on Thursday, November 7, 2019 at 4:30 pm Eastern Time to report financial results for its third quarter ended September 30, 2019 and provide a business update.
-
Takeaways from ASHG 2019 in Houston: Users of Bionano's Saphyr System Presented Validation Results for FSHD, Repeat Expansion Disorders and Digital Cytogenetics Among a Growing List of Applications of Saphyr in Human Genetics and Cancer Research
10/24/2019
Saphyr provides a platform that streamlines traditional workflows and provides a path to solving previously intractable scientific questions connected to the mechanisms of disease
-
Bionano Genomics Announces Pricing of $18 Million Underwritten Public Offering
10/21/2019
Bionano Genomics, INC. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today announced the pricing of an underwritten public offering.
-
Bionano Genomics Announces Adoption of Its Saphyr® System by Clinical Cytogenetics Groups in Academia and Industry to Replace Traditional Methods for Clinical Testing
10/16/2019
Successful validation of Saphyr to replace “gold standard” method of southern blotting for molecular diagnosis of FSHD supports broad utility of Saphyr
-
Preliminary Data Confirm Saphyr’s Potential to Replace Traditional Cytogenetics Methods for Detection of Structural Variants in Certain Blood Cancers
8/14/2019
Strong concordance with standard of care methods shows how Saphyr can transform cytogenetic workflows and provide an approach that may be faster and more cost-effective and may give better results
-
Bionano Genomics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2018
3/14/2019
Bionano Genomics, Inc. reported financial results for the fourth quarter and year ended December 31, 2018.
-
Bionano Genomics Enters Into Debt and Equity Financing Agreements Totaling $41.5 Million in Commitments
3/14/2019
Bionano Genomics, Inc. announced it has entered into financing agreements totaling $41.5 million in debt and equity commitments from affiliates of Innovatus Capital Partners, LLC, East West Bank and Aspire Capital Fund, LLC.
-
Bionano Genomics’ Saphyr® System Used for Highly Accurate Detection of the Genetic Disorder FSHD as an Alternative to Southern Blot
2/6/2019
Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, announces the release of a key publication by scientists at Wenzhou Medical University, Wenzhou Central Hospital, The First Hospital of Kunming and Berry Genomics, a leading provider of solutions for pre-natal diagnostic testing in China.